Skip To Main Content
Yinghua Zeng on Muck Rack

Yinghua Zeng

As seen in: Nature, ACS Publications
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Yinghua

Contact Yinghua, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Engineered Peptide Coassembly Enables Precision Delivery of As(III)-Peptide Complexes and Counteracts Inflammation-Dependent Therapeutic Resistance in High-Risk Neuroblastoma Click to copy article link Article link copied!

|
By Yinghua Zeng, Weiqi Zhang, Jieling Chen
| dx.doi.org
Open in Who Shared Issue with article?

Peptide-Amphiphilic Nanoassemblies as a Responsive Senolytic Navigator for Targeted Removal of Senescent Cardiomyocytes to Ameliorate Heart Failure

|
By Zhiye Wu, Yinghua Zeng, Huiming Chen, Zhengnan Xiao
| ACS Publications
Biological and Medical Applications of Materials and InterfacesSeptember 13, 2024 Zhiye Wu Guangdong Provincial Biomedical Engineering Technology Research Center for Cardiovascular Disease, Department of Cardiology and Laboratory of Heart Center, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, China Yinghua Zeng Guangdong Provincial Biomedical Engineering Technology Research Center for Cardiovascular Disease, Department of Cardiology and Laboratory of Heart Center, Zhujiang...
Open in Who Shared Issue with article?

An in-situ peptide-antibody self-assembly to block CD47 and CD24 signaling enhances macrophage-mediated phagocytosis and anti-tumor immune responses - Nature Communications

|
By Weiqi Zhang, Jie Zhan, Yinghua Zeng
| Nature Verified
Abstract Targeted immunomodulation for reactivating innate cells, especially macrophages, holds great promise to complement current adaptive immunotherapy. Nevertheless, there is still a lack of high-performance therapeutics for blocking macrophage phagocytosis checkpoint inhibitors in solid tumors.
Open in Who Shared Issue with article?
See all 3 articles